The U.S. FDA has approved Roche’s Wilserdly (giredestrant) in combination with everolimus for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer.
The approval covers patients whose disease has recurred during or after endocrine-based adjuvant therapy or progressed after at least one endocrine-based regimen in the metastatic setting. The combination is an all-oral treatment option for patients whose tumors have developed resistance to endocrine therapy.
The approval was supported by results from the phase 3 evERA Breast Cancer trial, which evaluated giredestrant plus everolimus against standard endocrine therapy plus everolimus in patients whose disease had progressed following treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor. Among patients with ESR1 mutations, the combination reduced the risk of disease progression or death by 62% compared with the control regimen.
Giredestrant is a next-generation oral selective estrogen receptor degrader (SERD) designed to block estrogen from binding to the estrogen receptor and trigger degradation of the receptor protein. Everolimus inhibits the mTOR signaling pathway, providing a second mechanism of action to address tumor growth and treatment resistance.
Roche is also pursuing an earlier-stage indication for giredestrant. The FDA is reviewing the drug as an adjuvant treatment for adults with ER-positive, HER2-negative stage 1, 2 and 3 breast cancer at intermediate to high risk of recurrence. The application, supported by phase 3 lidERA trial results, received Priority Review, with an FDA decision expected by Nov. 30, 2026.